These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28216276)

  • 21. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
    Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
    Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
    Kroeger N; Xie W; Lee JL; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Kollmannsberger CK; Tan MH; North SA; Rini BI; Choueiri TK; Heng DY
    Cancer; 2013 Aug; 119(16):2999-3006. PubMed ID: 23696129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.
    Amato RJ; Flaherty A; Zhang Y; Ouyang F; Mohlere V
    Urol Oncol; 2014 Apr; 32(3):345-54. PubMed ID: 24321256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM
    Fishman M; Dutcher JP; Clark JI; Alva A; Miletello GP; Curti B; Agarwal N; Hauke R; Mahoney KM; Moon H; Treisman J; Tykodi SS; Daniels G; Morse MA; Wong MKK; Kaufman H; Gregory N; McDermott DF
    J Immunother Cancer; 2019 Mar; 7(1):84. PubMed ID: 30917871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib.
    Cushen SJ; Power DG; Teo MY; MacEneaney P; Maher MM; McDermott R; O'Sullivan K; Ryan AM
    Am J Clin Oncol; 2017 Feb; 40(1):47-52. PubMed ID: 24685884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
    Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis.
    Buchler T; Bortlicek Z; Poprach A; Kubackova K; Kiss I; Zemanova M; Fiala O; Dusek L; Vyzula R; Melichar B;
    Urol Oncol; 2014 Jul; 32(5):569-75. PubMed ID: 24629497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
    Iacovelli R; De Giorgi U; Galli L; Zucali P; Nolè F; Sabbatini R; Fraccon AP; Basso U; Mosca A; Atzori F; Santini D; Facchini G; Fornarini G; Pasini F; Masini C; Massari F; Buti S; Sava T; Sacco C; Ricotta R; Sperduti I; Tortora G; Porta C
    Clin Genitourin Cancer; 2018 Oct; 16(5):355-359.e1. PubMed ID: 29803346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
    Nouhaud FX; Rebibo JD; Blanchard F; Sabourin JC; Di Fiore F; Pfister C
    Prog Urol; 2014 Jul; 24(9):563-71. PubMed ID: 24975791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Tanabe K
    Target Oncol; 2018 Dec; 13(6):745-755. PubMed ID: 30328067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus.
    Conteduca V; Santoni M; Medri M; Scarpi E; Burattini L; Lolli C; Rossi L; Savini A; Berardi R; Stanganelli I; Cascinu S; De Giorgi U
    Clin Genitourin Cancer; 2016 Oct; 14(5):426-431. PubMed ID: 27021585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.
    Stein A; Bellmunt J; Escudier B; Kim D; Stergiopoulos SG; Mietlowski W; Motzer RJ;
    Eur Urol; 2013 Dec; 64(6):994-1002. PubMed ID: 23219086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
    Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
    Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
    Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
    Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
    Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
    Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.